Biosynex SA (EPA:ALBIO)

France · Delayed Price · Currency is EUR

0.9040

-0.0060 (-0.66%)

Jul 30, 2026, 5:35 PM CET

-25.29% (1Y)

Market Cap	16.66M -27.2%
Revenue (ttm)	95.19M -5.9%
Net Income	-58.22M
EPS	-3.16
Shares Out	18.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,464
Open	0.9020
Previous Close	0.9100
Day's Range	0.9000 - 0.9320
52-Week Range	0.4550 - 1.5700
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizi... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2005

Employees 397

Stock Exchange Euronext Paris

Ticker Symbol ALBIO

Full Company Profile

Financial Performance

In 2025, Biosynex's revenue was 95.19 million, a decrease of -5.90% compared to the previous year's 101.17 million. Losses were -58.22 million, 34.4% more than in 2024.

Financial Statements